DDA1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P09596(DDA1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

DDA1 (DET1 and DDB1-associated protein 1) is a protein that has garnered interest due to its role in the ubiquitin-proteasome system, a critical pathway for protein degradation and cellular regulation. Initially identified as a binding partner of DDB1 (DNA damage-binding protein 1) and CUL4A (Cullin 4A), DDA1 is a component of the CUL4-DDB1 ubiquitin ligase complex, which participates in substrate recognition and ubiquitination. This complex is involved in diverse cellular processes, including DNA repair, cell cycle control, and transcriptional regulation. Dysregulation of ubiquitination pathways is frequently linked to diseases such as cancer, making DDA1 a subject of research in oncology.

Studies suggest that DDA1 may act as an oncogene or tumor suppressor depending on cellular context. For instance, elevated DDA1 expression has been observed in certain cancers, such as prostate and lung cancer, where it potentially promotes tumor progression by destabilizing tumor-suppressive proteins. Conversely, reduced DDA1 levels have been implicated in hepatocellular carcinoma, indicating a complex, tissue-specific role.

DDA1 antibodies are essential tools for investigating these mechanisms. They enable detection of DDA1 expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers also use these antibodies to study protein-protein interactions, particularly within the CUL4-DDB1 complex, to elucidate DDA1’s regulatory functions. Emerging evidence highlights its potential as a biomarker or therapeutic target, driving further exploration into its molecular interactions and disease relevance.